Lykos Therapeutics is not taking the rejection of midomafetamine lying down. The company said late on 9 August that the product, a version of the illicit drug MDMA for the treatment of post-traumatic stress disorder, had been knocked back by the US Food and Drug Administration. But Lykos plans to request a meeting with the agency so it can plead for a rethink.
Key Takeaways
- Lykos Therapeutics’ approval application for midomafetamine was rejected by the FDA late last week.
Whether the FDA will reconsider its decision is far from clear. Certainly it has given in to appeals before –...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
